SCHEMBL30773849

CC[C@@H](C)[C@@H](NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(N)=O

nearest known ligand 0.67

Predicted protein targets (top 8)

	gene	UniProt	supporting neighbours	confidence
▸	NPBWR1	P48145	11/20	0.67

▸	RXFP1	Q9HBX9	1/20	0.65

▸	IL23R	Q5VWK5	5/20	0.64

▸	GLP1R	P43220	2/20	0.63

▸	CCKBR	P32239	1/20	0.63

▸	PTH1R	Q03431	1/20	0.61

▸	GCGR	P47871	1/20	0.59

▸	GIPR	P48546	1/20	0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29669730	0.97	NPBWR1 (0.64)	NPBWR1RXFP1IL23RGLP1RCCKBR
SCHEMBL30773786	0.95	NPBWR1 (0.68)	NPBWR1RXFP1IL23RGLP1RCCKBR
SCHEMBL30773852	0.95	NPBWR1 (0.69)	NPBWR1RXFP1IL23RGLP1RCCKBR
SCHEMBL29669569	0.95	NPBWR1 (0.66)	NPBWR1RXFP1IL23RGLP1RCCKBR
SCHEMBL29669608	0.92	NPBWR1 (0.65)	NPBWR1RXFP1IL23RGLP1RCCKBR
SCHEMBL29669568	0.92	NPBWR1 (0.66)	NPBWR1RXFP1IL23RGLP1RCCKBR
SCHEMBL29669637	0.92	NPBWR1 (0.71)	NPBWR1
SCHEMBL29669735	0.91	RXFP1 (0.64)	NPBWR1RXFP1IL23RGLP1RCCKBR
SCHEMBL30773757	0.91	NPBWR1 (0.63)	NPBWR1RXFP1PTH1R
SCHEMBL31182951	0.89	GLP1R (0.73)	RXFP1IL23RGLP1RCCKBRPTH1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12459973-B2	Peptide compounds for reducing side effects of CB1 receptor agonists	UNIVERSITAT DE BARCELONA (ES)	2025-11-04	—	—	US	disclosed
US-20240059737-A1	PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS	UNIVERSITAT POMPEU FABRA (ES)	2024-02-22	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12459973-B2	Peptide compounds for reducing side effects of CB1 receptor agonists	CNR2, CNR1, OPRD1	NPBWR1 51/4885RXFP1 53/4885IL23R 2270/4885
US-20240059737-A1	PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS	CNR2, CNR1, OPRD1	NPBWR1 53/4885RXFP1 49/4885IL23R 2296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.